Clinical Trial: Endostatin Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tumors

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: Recombinant Human Endostatin Injection Study for Patients With Neurofibromatosis Type 2 (NF2) and NF2-Related Tum

Brief Summary: 1)Preliminarily evaluate the treatment effect of continuous vein injection of recombinant human endostatin on NF2; 2)Preliminarily evaluate the safety and the patient's tolerance of the treatment of endostatin; 3)Provide an objective basis for an enlarged randomized double-blind trial.

Detailed Summary:

Neurofibromatosis type 2 (NF2) is a hereditary tumor predisposition syndrome caused by mutations in the NF2 tumor suppressor gene. Individuals with NF2 have a higher likelihood to develop multiple nervous system tumors, including schwannomas, meningiomas, and ependymomas. The hallmark of NF2 is bilateral vestibular schwannomas. Historically, most NF2 patients experience complete hearing loss either from tumor progression or after treatment of the tumors with surgery or radiation. Effective treatments are urgently needed for NF2 patients with progressive hearing loss because hearing loss is associated with impairment in social, emotional,and communication function and with increased depression.

Previous studies of NF2 patients treated with bevacizumab suggested that inhibition of vascular endothelial growth factor (VEGF) could result in hearing improvement and reduction in tumor size.Recombinant human endostatin can inhibit the formation of blood vessels by inhibiting the migration of vascular endothelial cells .In this way, endostatin can inhibit the nutrition of the tumor and decrease the tumor's growth and metastasis. In vitro tests, endostatin can inhibit the cell migration and Tube formation of the microvascular endothelial cell line HHEC. Besides, it can inhibit blood vessels' formation of the chicken embryo sac membrane. Based on these studies, we perform this clinical trial to known the treatment effect and tolerability of endostatin on NF2.


Sponsor: Beijing Tiantan Hospital

Current Primary Outcome: Change from Baseline in volume of tumour after every course of the treatment [ Time Frame: Baseline,Month 3,Month 7,Month 11 ]

Patients in this clinical trial would receive MRI test to evaluate the volume of tumour after every course of the treatment.


Original Primary Outcome: Same as current

Current Secondary Outcome: Change from Baseline in hearing ability after every course of the treatment [ Time Frame: Baseline,Month 3,Month 7,Month 11 ]

Patients' hearing ability would be tested after every course of the treatment.


Original Secondary Outcome: Same as current

Information By: Beijing Tiantan Hospital

Dates:
Date Received: March 26, 2014
Date Started: January 2014
Date Completion:
Last Updated: February 7, 2017
Last Verified: February 2017